The right cancer sample, every time.
NextGen Sample Solutions delivers comprehensively characterized liquid biopsy samples with known cfDNA yield — so your R&D moves forward predictably and more cost efficient.
Up to 75% of blood samples used in cancer diagnosis R&D and validation are useless.
The clinical sample bottleneck slows discovery, inflates budgets, and stalls breakthrough diagnostics. We've spent careers solving it.
Yield minimal usable material
Half of biospecimens fail to deliver enough cfDNA for downstream assays.
Biomarker concordance with tissue
Tissue-derived data doesn't reliably translate to liquid biopsy programs.
Unknown cfDNA biomarkers
Researchers operate blind — without characterization of what's truly in plasma.
Comprehensive genomic-profiled liquid biopsies — with known cfDNA.
Three problems. Three answers. One sample that actually works.
Identify high-yielding samples
We pre-screen and select only specimens with the cfDNA mass your workflow needs.
Don't rely on tissue data
Decisions backed by liquid biopsy biomarker data — not extrapolations from tissue.
Test the liquid biopsies directly
Comprehensive genomic profiling on every sample so you know exactly what you're buying.
The only supplier offering the full characterization stack.
Happier customers. 50–90% cost reduction.
| Product Offering | NGSS | Reference Medicine | Discovery Life Sci. | Precision for Med. | iSpecimen |
|---|---|---|---|---|---|
| Uncharacterized Plasma | |||||
| Plasma with CGP Data | — | — | — | ||
| Plasma with cfDNA Yield | — | — | — | — | |
| cfDNA by Mass | — | — | — | — | |
| Customized Clinical cfDNA | — | — | — | — |
A growing market with immense potential.
~5,000 priority organizations purchasing 50 samples annually at ~$5,400 per sample. Liquid biopsy is one of the fastest-growing categories in oncology research supply.
- Market-validated pricing & demand
- Ranked #1 in usefulness by surveyed buyers
We're raising capital to launch NextGen Sample Solutions.
NGSS is pre-launch and actively raising to stand up operations, secure biospecimen partnerships, and deliver the first characterized liquid biopsy samples to customers. We're talking with mission-aligned investors who want to help fix the cancer diagnostics sample bottleneck.
- StagePre-launch — raising founding round
- Use of fundsOperations, sample sourcing, characterization workflow
- Who we're talking toStrategic angels and early-stage life-science investors
Two ways to get involved.
Reserve early access to characterized cohorts as a researcher, or request investor materials if you're exploring the round.
We'll only use your information to follow up about NextGen Sample Solutions. No marketing list rentals, ever.